z-logo
Premium
Do Blood Pressure Levels and Other Patient Characteristics Influence Native Fistula Patency?
Author(s) -
Irvinn Jeyna,
Oldman Nicola,
Sedgwick Philip,
Chemla Eric
Publication year - 2013
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/sdi.12163
Subject(s) - medicine , blood pressure , warfarin , clopidogrel , aspirin , hemodialysis , odds ratio , fistula , cardiology , thrombosis , retrospective cohort study , surgery , atrial fibrillation
Arteriovenous fistulas ( AVF s) play an important role in access for hemodialysis, yet premature thrombosis is a challenge. This study identifies factors influencing primary patency in a series of AVF creations. Postoperative systolic blood pressure ( BP ) was of principal interest; demographical information, comorbidities, smoking status, warfarin, aspirin, clopidogrel, and statins were considered. A retrospective review of AVF creations performed by one surgeon between January 2008 and September 2010 was conducted. Fistula patency was denoted by a bruit and measured at 3 weeks and 12 months after surgery. One hundred and fifty‐one AVF creations were studied; 134 fistulas (88.7%) were patent at 3 weeks and 85 (56.3%) at 12 months. The odds ratio ( OR ) for thrombosis at 12 months was 0.16 (95% CI: 0.04, 0.62; p  = 0.008) among patients with a postoperative systolic BP of 120–139 mmHg compared with those with a BP of ≤119 mmHg. Patients taking warfarin yielded an OR of 5.71 at 3 weeks (95% CI: 1.20, 27.11; p  = 0.028), and 3.33 at 12 months (95% CI: 1.01, 10.99; p  = 0.048). No other variables were statistically significant. Patients with postoperative systolic BP of 120–139 mmHg showed a reduction in fistula thromboses compared with patients with a systolic BP of ≤119 mmHg. Patients on warfarin were less likely to maintain a patent fistula.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom